MENU
DEC 03, 2020 7:30 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Keynote Presentation: Prevalence of SARS-CoV-2 Immunity in Those Undiagnosed with COVID-19 in the U.S.

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director, LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
    Biography

      Dr. Memoli is a graduate of the College of William and Mary and he received his master’s degree in microbiology from Thomas Jefferson University in Philadelphia, PA. He then received his medical degree from St George’s University School of Medicine. He completed a residency in internal medicine at the Washington Hospital Center Georgetown University Internal Medicine Program in Washington, DC. After completing an infectious disease fellowship in NIAID at the National Institutes of Health, Dr. Memoli developed a clinical/translational research program to study influenza and other respiratory viruses in the Laboratory of Infectious Diseases. He now serves as the Director of the LID Clinical Studies Unit (CSU) that seeks to perform translational research studies to answer fundamental questions regarding human influenza, respiratory viruses, and other emerging viral infections to inform and impact future vaccine and therapeutic design, while also making an effort to assist in evaluation of novel products that may impact human health. With a focus on healthy volunteer research, the LID CSU has been able to continue their primary work on influenza while quickly able to respond to assist in research of emerging infections.  Dr. Memoli is considered a leading expert in healthy volunteer challenge trials, respiratory virus infections, and influenza vaccines. In addition, in recent years Dr. Memoli’s LID CSU has been heavily involved in the NIH response to emerging threats including the 2009 Influenza Pandemic, Zika, EBOLA, and COVID19.


    Abstract

    Learning Objectives:

    1. Define SARS-CoV-2 immunity, antibody testing, and discuss what is known about the meaning of these tests

    2. Identify challenges in doing research during social distancing and demonstrate methods to overcome those challenges

    3. Explain the findings of the NIH serosurvey in terms of prevalence of SARS-CoV-2 immunity by geography and demographic groups


    Show Resources
    You May Also Like
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    SEP 17, 2020 2:00 PM PDT
    C.E. CREDITS
    SEP 17, 2020 2:00 PM PDT
    Learning Objectives: 1. Understanding the integral value of collaboration for advancement in scientific research; how to establish and grow academic, Pharma, and industry connections 2. Lear...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    Loading Comments...
    Show Resources
    Event Countdown
    • 0 Days
    • 0 Hours
    • 0 Minutes
    • 0 Seconds
    Attendees
    • See more